10.06

3.18% 0.31

After Hours: 10.06

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $10.06, with a volume of 988.14K. It is up +3.18% in the last 24 hours and down -9.69% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$9.75

Open:

$9.69

24h Volume:

988.14K

Relative Volume:

0.89

Market Cap:

$1.54B

Revenue:

$61.10M

Net Income/Loss:

$-138.36M

P/E Ratio:

-8.3833

EPS:

-1.2

Net Cash Flow:

$-90.59M

1W Performance:

+14.58%

1M Performance:

-9.69%

6M Performance:

+73.60%

1Y Performance:

+351.12%

1-Day Range:

$9.31

$10.25

1-Week Range:

$8.21

$10.25

52-Week Range:

$2.16

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

267

Twitter

@OCUTX

Next Earnings Date

2024-11-05

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	10.06	1.54B	61.10M	-138.36M	-90.59M	-1.20
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

Nov 27, 2024

Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Canada

Nov 27, 2024

Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria

Nov 27, 2024

Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com

Nov 27, 2024

Ocular Therapeutix executive sells shares for $16,326 - Investing.com

Nov 27, 2024

Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com

Nov 27, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 27, 2024

Nov 26, 2024

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire

Nov 26, 2024

Nov 24, 2024

OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 23, 2024

Nov 20, 2024

Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 16, 2024

GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Nov 16, 2024

Nov 15, 2024

Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat

Nov 15, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024